Highest-materiality recent filing
BioMarin provides Amicus audited 2025 financials; revenue $634M, net loss $27M
Amicus 2025 net product sales $634.2M, up 20% YoY from $528.3M; net loss narrowed to $27.1M from $56.1M.
BioMarin Q1 revenue up 3% to $766M; EPS down; raises FY2026 guidance to $3.825-$3.925B
Total revenues $766M (+3% YoY); GAAP net income $106M (down 43%) vs $186M.
BioMarin completes $4.8B acquisition of Amicus Therapeutics; adds Galafold, Pombiliti+Opfolda
Acquired Amicus for $14.50/share in cash; total equity value ~$4.8B.
BioMarin receives French FDI clearance for Amicus merger; closing expected April 27, 2026
French Ministry of Economics and Finance granted FDI clearance for merger with Amicus on April 23, 2026.
BioMarin discontinues VOXZOGO trials in Turner, SHOX, ACAN after SCFE safety events
Discontinued dosing and enrollment in Phase 2 CANOPY trials for Turner syndrome, SHOX-deficiency, and ACAN-deficiency.
BioMarin Q4 rev $875M (+17% Y/Y); GAAP net loss $47M on ROCTAVIAN withdrawal; Amicus deal on track
Q4 total revenues $875M (+17% Y/Y); full-year $3.22B (+13% Y/Y).
BioMarin closes $850M 5.500% senior notes offering to fund Amicus acquisition
Closed private placement of $850M 5.500% senior notes due 2034 at 100% issue price.
BioMarin prices $850M 5.500% notes due 2034 and syndicates $2B term loan for Amicus acquisition
$850M 5.500% senior notes due 2034; price 100%; expected close Feb 12, 2026.
BioMarin guides ~$3.2B FY2025 revenue; plans $850M notes + $2.8B loans for Amicus deal
FY2025 preliminary total revenue ~$3.2B, including ~$920M from VOXZOGO; cash & investments ~$2.1B.
BioMarin estimates FY2025 revenue ~$3.2B; expects $230-260M ROCTAVIAN asset write-down
Preliminary FY2025 total revenue ~$3.2B, with VOXZOGO contributing ~$920M.
BioMarin to acquire Amicus Therapeutics for $4.8B in all-cash deal at $14.50/share
BioMarin acquires Amicus for $14.50/share in cash, total equity value ~$4.8B; expected Q2 2026 close.
BioMarin Q3 net loss $31M vs income $106M YoY; revenue +4% to $776M; guidance raised
GAAP net loss of $31M (diluted EPS -$0.16) vs income $106M ($0.55) in Q3 2024, due to $221M IPR&D charge from Inozyme acquisition.
BioMarin expects $221M IPR&D charge from Inozyme acquisition, ~$1.10 EPS hit in Q3 2025
Acquired IPR&D charge of ~$221M pre-tax from July 1 Inozyme Pharma acquisition.
BioMarin Q2 revenue $825M (+16% Y/Y); GAAP EPS $1.23 (+124%); raises full-year guidance
Total revenue $825M, +16% Y/Y; GAAP net income $241M (vs $107M) and diluted EPS $1.23 (+124%).
BioMarin acquires Inozyme for $4.00/share (~$270M cash); adds late-stage ENPP1 therapy
All-cash tender offer at $4.00 per share; total equity value ~$270M; expected to close Q3 2025.
BioMarin Q1 2025 revenue $745M (+15% YoY), GAAP EPS $0.95, reaffirms 2025 guidance
Q1 total revenues $745M (+15% Y/Y); GAAP net income $186M (+109% Y/Y); non-GAAP income $221M (+58% Y/Y).
BioMarin reports Q4 revenue $747M (+16%), full-year GAAP EPS $2.21, guides 2025 rev growth ~10%
Q4 total revenue $747M (+16% YoY); full-year $2.854B (+18%). GAAP diluted EPS $0.64 (Q4) and $2.21 (FY), up 154% YoY.
BioMarin Q3 revenue $746M (+28% YoY), GAAP EPS $0.55 (+162%), raises FY2024 guidance
Total revenues $746M (+28% YoY); VOXZOGO revenue +54% YoY; enzyme therapies +27%.
BioMarin reaffirms long-term guidance: ~$4B revenue by 2027, 40% margin from 2026
Reaffirms ~$4B total revenues in 2027.
BioMarin to cut ~225 jobs, incur $30-35M in severance costs by end of 2024
Workforce reduction of ~225 employees committed on Aug 23, 2024, in organizational redesign.
BioMarin Q2 revenue $712M (+20% YoY), GAAP EPS $0.55 (+90%), raises FY2024 guidance
VOXZOGO revenue $183.9M (+62% YoY); ~3,500 children on treatment across 44 countries.
BioMarin Q1 revenue $649M (+9% YoY); raises non-GAAP EPS and margin guidance
GAAP diluted EPS $0.46 (+70% YoY); Non-GAAP diluted EPS $0.71 (+18% YoY).
BioMarin reports record FY2023 revenue $2.42B (+15% YoY); non-GAAP EPS $2.08 (+36% YoY)
FY2023 total revenues $2.42B (+15% YoY); GAAP diluted EPS $0.87 (+16% YoY); non-GAAP diluted EPS $2.08 (+36% YoY).
BioMarin settles with Elliott; appoints 3 new directors, forms strategic review committee
Board expanded to 15 directors; appoints Barbara Bodem, Athena Countouriotis, Mark Enyedy as independent directors effective Dec 27, 2023.
BioMarin CEO Jean-Jacques Bienaimé retiring; Alexander Hardy appointed new CEO
Jean-Jacques Bienaimé retires as President, CEO and Chairman on Nov 30, 2023; remains on board until 2024 annual meeting.
BioMarin Q3 2023: revenue $581M (+15% YoY), VOXZOGO $123M (+155%), cuts ROCTAVIAN guidance
Q3 total revenue $581.3M (+15% YoY), GAAP net income $40.4M vs loss $6.7M, GAAP diluted EPS $0.21 vs ($0.04).
BioMarin Q2 revenues $595M (+12% YoY), raises FY VOXZOGO guidance to $400-440M
Q2 total revenues $595.3M (+12% YoY); GAAP net income $56.0M ($0.29 diluted EPS); Non-GAAP income $105.2M ($0.54 diluted EPS).
BioMarin Q1 revenue $596.4M (+15% YoY); VOXZOGO guidance raised to $380-$430M
GAAP diluted EPS $0.27 (down from $0.63 due to $89M prior-year PRV gain); Non-GAAP EPS $0.60 (up from $0.52).
BioMarin reports record Q4 revenues $537.5M (+19% YoY); guides 2023 total rev $2.375-2.5B
Q4 total revenues $537.5M, up 19% YoY; full year $2.096B, up 14%.
BioMarin estimates FY2022 total revenue of $2.09B, VOXZOGO sales $169M
Preliminary unaudited total revenue for FY2022 estimated at $2.09 billion.
BioMarin Q3 revenue up 24% YoY to $505M; VOXZOGO guidance raised to $140-170M
Total revenues $505.3M (+24% YoY); GAAP net loss narrowed to $6.7M from $36.5M; Non-GAAP income $82.7M.
BioMarin cuts ~120 jobs, expects $50M annual savings to reinvest
Workforce reduction of ~120 employees; pre-tax charges of $20-25M in Q3/Q4 2022.
BMN 270 phase 3 participant diagnosed with B-ALL; 85% of leukemic cells had Ph-like translocation.
BioMarin reports record Q2 revenues of $534M; raises FY2022 guidance on Voxzogo growth
Total revenues $533.8M (+6% YoY); GAAP net income $27.7M vs $12.9M in Q2 2021.
the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.
On August 16, 2024, Dr. Henry J. Fuchs advised BioMarin Pharmaceutical Inc. (the “Company”) that he has elected to retire from the Company effective March 3, 2025 (the “Retirement Date”).
He will continue in his current role until Dr. Greg Friberg assumes the position of Executive Vice President, Chief Worldwide Research and Development Officer, which is expected on September 30, 2024.
On January 11, 2024, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) announced that Mr. Jeffrey Ajer would step down as the Company’s Executive Vice President and Chief Commercial Officer, effective July 1, 2024.
On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.
On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.
On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.
Richard A. Meier, BioMarin’s lead independent director, will assume the role of Chair of the Board, effective December 1, 2023.
Jean-Jacques Bienaimé will retire as the Company’s President, Chairman and Chief Executive Officer effective as of close of business on November 30, 2023
the Company announced the appointment of Alexander Hardy, age 55, to serve as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of December 1, 2023
On May 05, 2022., BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) announced the appointment of Erin Burkhart as BioMarin’s Group Vice President, Chief Accounting Officer, effective May 2, 2022.
appointed Mark J. Alles to the Board and to the Audit Committee of the Board, to be effective January 1, 2022.
Max materiality 0.90 · Median 0.75 · Most common event earnings